The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study

Gao, Dengfeng; Xu, Min; Wang, Gang; Lv, Jianrui; Ma, Xiaoli; Guo, Yi; Zhang, Dexin; Yang, Haojie; Wei, Jue; Deng, Feng; Xia, Guozhi; Lu, Ziwei; Lv, Lv; Gong, Shengjie

doi:10.18632/aging.202557

Cited by 73 publications

(87 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vitamin C can improve the resistance of white blood cells to viruses, has an antioxidant effect, and can induce interferon production in vivo. [ 4 , 19 ] In viral infections, vitamin C can attenuate pro-inflammatory response, enhance epithelial barrier function, increase alveolar fluid clearance rate, and prevent sepsis related coagulation abnormalities. [ 20 ] The implementation of high-dose vitamin C treatment can significantly reduce the demand for high-dose corticosteroids, antibiotics, and antiviral drugs, as these drugs may have the effects of immunosuppression, adrenal suppression and toxicity, complicating the course of the disease.…”

Section: Discussionmentioning

confidence: 99%

High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19

Huang¹,

Wang²,

Tan³

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Patients infected with a virus usually lack vitamin C. High-dose vitamin C has an antiviral effect, and has been used by several researchers to treat COVID-19 by intravenous infusion, achieving good results. However, the efficacy and safety of vitamin C in the treatment of patients with COVID-19 remain unclear. Thus, the aim of the present study was to investigate the efficacy of high-dose vitamin C infusion in the treatment of patients with COVID-19. Methods: Electronic databases were searched, including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science, China National Knowledge Infrastructure database, Chinese Wanfang database, and Chinese Biomedical Literature database. The aim was to collect randomized controlled trials of high-dose vitamin C infusion in the treatment of patients with COVID-19, with the retrieval time being from the establishment of the database to March 2021. In accordance with the pre-designed inclusion/exclusion criteria, all data were extracted independently by 2 researchers. To assess the risk bias in the studies, the Cochrane collaboration's tool for assessing risk of bias was used to assess the risk bias in the studies, while meta-analysis was performed using Revman 5.3 software. Results: In the present study, a high-quality comprehensive evaluation is provided of high-dose vitamin C infusion in the treatment of patients with COVID-19. Conclusion: Further convincing evidence for the clinical treatment of COVID-19 is provided, in addition to evidence-based guidance for clinical practice. PROSPERO Registration Number: CRD42021246342.

show abstract

Section: Discussionmentioning

confidence: 99%

High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19

Huang¹,

Wang²,

Tan³

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

“…The sample size was calculated according to hs-CRP from the study regarding the effect of HIVC on hs-CRP in COVID-19 patients. [7] We used a non-inferiority test for the sample size calculation based on the parameters: α = 0.025 (two-sided), power: 1-β = 0.8, a withdrawal rate of 10% in each group, 2:1 ratio of the control group to the intervention group. The resulting total sample size is fixed to 135 with 90 patients in the control group and 45 patients in the intervention group.…”

Section: Methodsmentioning

confidence: 99%

High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019

Xia

Fan

et al. 2021

Nutrition

Self Cite

View full text Add to dashboard Cite

Background High-dose intravenous vitamin C (HIVC) is a major concern on treating coronavirus disease 2019 (COVID-19). Objective To assess the clinical efficacy of HIVC on hyperinflammation among patients with severe COVID-19. Methods The retrospective cohort study included inpatients with severe COVID-19, a subset of whom was treated with HIVC. The medical records were screened for demographic data, laboratory findings, medications, as well as initial and repeated values of multiple inflammatory markers for analysis. Results The percentages of patients presented hyperinflammation based on inflammatory markers levels above upper limit of normal (hs-CRP, 80.1%; IL-6, 91.5%; TNF-a, 67.4%). A total of 85 (36.0%) patients received HIVC therapy. After treatment with HIVC, the levels of inflammatory markers displayed significant decrease related to those among patients without HIVC. Furthermore, the percentages of reduction in inflammatory markers levels were higher in patients receiving HIVC compared with those in patients treated without HIVC. Stepwise multiple linear regression analysis revealed that HIVC was independently associated with percentages of reduction in inflammatory markers levels. Conclusions HIVC has potential benefit in attenuating hyperinflammation through reducing inflammatory markers levels in patients with severe COVID-19.

show abstract

“…In addition, the patients with a high dose of vitamin C had reduced serum high sensitivity-C-reactive protein, procalcitonin and IL-8 levels in comparison with the standard group. Finally the patients with a high dose of vitamin C did not show adverse effects [ 258 ]. In a retrospective case series study, vitamin C significantly decreased serum C-reactive protein from 0 to 3 after 7 days of administration in six patients infected with severe and six patients with critical COVID-19.…”

Section: Antioxidants As Neuroprotectors In Patients Infected With Covid-19mentioning

confidence: 99%

Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19

et al. 2021

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is an emergent infectious disease that has caused millions of deaths throughout the world. COVID-19 infection’s main symptoms are fever, cough, fatigue, and neurological manifestations such as headache, myalgias, anosmia, ageusia, impaired consciousness, seizures, and even neuromuscular junctions’ disorders. In addition, it is known that this disease causes a series of systemic complications such as adverse respiratory distress syndrome, cardiac injury, acute kidney injury, and liver dysfunction. Due to the neurological symptoms associated with COVID-19, damage in the central nervous system has been suggested as well as the neuroinvasive potential of SARS-CoV-2. It is known that CoV infections are associated with an inflammation process related to the imbalance of the antioxidant system; cellular changes caused by oxidative stress contribute to brain tissue damage. Although anti-COVID-19 vaccines are under development, there is no specific treatment for COVID-19 and its clinical manifestations and complications; only supportive treatments with immunomodulators, anti-vascular endothelial growth factors, modulating drugs, statins, or nutritional supplements have been used. In the present work, we analyzed the potential of antioxidants as adjuvants for the treatment of COVID-19 and specifically their possible role in preventing or decreasing the neurological manifestations and neurological complications present in the disease.

show abstract

The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study

Cited by 73 publications

References 45 publications

High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19

High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19

High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019

Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19

Contact Info

Product

Resources

About